Clinical Trial Update: Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating autologous CD8+ T cells engineered to express an anti-BCMA CAR for multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Autologous CD8+ T-cells expressing an anti-BCMA CAR

Snippet

Sponsor: Cartesian Therapeutics | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED